# Effects of Xipayi Gingival Solution combined with minocycline hydrochloride on inflammatory cytokines and masticatory function in patients with chronic periodontitis

**Authors:** Meijie Shen, Yanjie Chai, Shenxi Yao, Lijie Xu

PMC · DOI: 10.3389/fcimb.2026.1739777 · 2026-02-25

## TL;DR

Combining Xipayi Gingival Solution with minocycline improves periodontal health, reduces inflammation, and enhances chewing function in chronic periodontitis patients.

## Contribution

Demonstrates that combining Xipayi Gingival Solution with minocycline provides better clinical outcomes than minocycline alone.

## Key findings

- Combination therapy reduced periodontal indicators more effectively than minocycline alone.
- Inflammatory and oxidative stress markers improved significantly in the combination group.
- Masticatory function improved and pain decreased more in patients using the combination therapy.

## Abstract

This study aimed to elucidate the therapeutic effects of Xipayi Gingival Solution (Xipayi Guyin Ye) combined with minocycline hydrochloride on inflammatory factors and masticatory function in patients with chronic periodontitis.

Ninety-eight patients with chronic periodontitis were randomly allocated into two groups. Both groups underwent conventional periodontal therapy. The control group received minocycline hydrochloride once weekly for four weeks, while the combination group additionally used Xipayi Gingival Solution three times daily for four consecutive weeks. Periodontal health indicators (PD, AL, PLI, SBI, GI, GCFV), gingival crevicular fluid cytokines (hs-CRP, TNF-α, IL-1β, IL-6), serum oxidative stress markers (MDA, SOD, GSH-Px), masticatory function (CFQ), pain (VAS), clinical efficacy, and adverse reactions were compared.

Four control and two combination group patients withdrew. Finally, 45 and 47 patients completed treatment. Post-treatment, PD, AL, PLI, SBI, GI, and GCFV decreased in both groups, with lower values in the combination group (P < 0.05). Inflammatory and oxidative stress markers improved more in the combination group (P < 0.05). CFQ scores increased and VAS scores decreased in both groups, with better outcomes in the combination group (P < 0.05). Total effective rate was higher in the combination group (97.87% vs 84.44%, P < 0.05), while adverse reactions were comparable (8.51% vs 4.26%, P > 0.05).

Xipayi Gingival Solution combined with minocycline hydrochloride enhances periodontal status, mitigates inflammatory and oxidative stress responses, improves masticatory function, and relieves pain without increasing adverse events. The combined therapy demonstrates better clinical efficacy than minocycline alone, indicating a safe and effective therapeutic approach for chronic periodontitis.

## Linked entities

- **Chemicals:** minocycline hydrochloride (PubChem CID 54685925), IL-6 (PubChem CID 165368475), MDA (PubChem CID 1614), GSH-Px (PubChem CID 168010211)
- **Diseases:** chronic periodontitis (MONDO:0005593)

## Full-text entities

- **Genes:** IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, SOD1 (superoxide dismutase 1) [NCBI Gene 6647] {aka ALS, ALS1, HEL-S-44, IPOA, SOD, STAHP}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}
- **Diseases:** Inflammatory (MESH:D007249), pain (MESH:D010146), chronic periodontitis (MESH:D055113)
- **Chemicals:** minocycline (MESH:D008911), AL (MESH:D000535), GCFV (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]

---
Source: https://tomesphere.com/paper/PMC12975867